TScan Therapeutics, Inc. cotiza a 0.22 USD y tiene una capitalización bursátil de $15M. En los últimos 12 meses ha facturado $7M con un margen de flujo de caja libre del -1353.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome …
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.23 | $-0.22 | $-0.18 | — |
| Estimado | $-0.20 | $-0.16 | $-0.28 | $-0.33 |
| Sorpresa | -15.0% | -37.5% | +35.7% | — |
| Métrica | TCRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -1315.4% | -38.6% | -1276.8% |
| Net Margin | -1256.8% | -33.6% | -1223.3% |
| FCF Margin | -1353.3% | -13.9% | -1339.4% |
| ROE | -105.4% | -40.4% | -65.0% |
| ROA | -56.7% | -32.0% | -24.7% |
| Current Ratio | 8.41 | 2.84 | +5.57 |
| Debt / Equity | 0.26 | 0.28 | -0.02 |